An FDA advisory panel endorsed the approval of MannKind's inhaled insulin therapy Afrezza as a treatment for type 1 and type 2 diabetes. Afrezza could especially benefit type 2 diabetes patients who have difficulty injecting themselves with insulin because of poor eyesight or hand arthritis, as well as patients with extreme fear of needles, the panel said. A final decision is expected by April 15.
MannKind's inhaled diabetes treatment wins FDA panel support
SmartBrief Job Listings for Health Care